Acute Stroke:
Deadly, Disabling, Undertreated
Current Treatment Pathway for Ischemic Stroke
Stroke is the second leading cause of death globally
- 1.7M annual cases in US, EU5, and Japan
- Adult global lifetime risk of AIS >18%
Current Treatments reach <15% of all Patients
- TPA associated bleeding risk limits utilization
- Clot accessibility and need for a surgeon limit usage of thrombectomy
Stroke is costly with poor outcomes
– Leading cause of long-term disability
~$240B annual US cost in 2030
Our Approach
Acute thrombolytic with reversal agent
DTRI-031 has demonstrated superiority to TPA across multiple murine and canine preclinical models while DTRI-025 provides rapid reversal in the event of bleeding.
Mechanism of Action
Target: von Willebrand Factor
– Non-redundant mediator of platelet adhesion/aggregation
– Prevalent throughout clot structure
– Proven relationship between vWF and risk of stroke/MI
Safety
Reversible and Short Duration
– Neutralization of drug effect in < 5 min if needed
– ~3-hour pharmacodynamic effect
– Well tolerated in GLP toxicology studies
Efficacy
Optimized for Stroke Therapy
– Superior to rTPA in multiple animal models
– Rapid onset of action (< 5 mins.)
– DTRI-025 allows hemostatic modulation
Funding Update
Our recently closed Seed Financing supports development of DTRI-031 through Phase 1B, in parallel with the NIH funded DTRI-025’s IND enabling program.